<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Tight competition for the first-line treatment of Hodgkin's lymphoma: a comprehensive review of practice-changing developments in recent years

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

Organization Authors

Co-Authors

Yilmaz, Umut

Atesoglu, Elif Birtas

Date

Language

Type

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

IntroductionThere has been a giant leap forward in the management of Hodgkin's lymphoma (HL) over the past decade. Emergence of long-term data from large, randomized trials in early-stage disease (eHL) and incorporation of brentuximab vedotin (BV) or nivolumab into the frontline setting through three large phase-3 trials in advanced stages (aHL) are driving the paradigm shift in HL. The new landscape promises chances of cure to over 90% newly diagnosed patients while maintaining caution for long-term toxicity.Areas coveredThis review will cover the published evidence regarding primary analyses or updates within the last 5 years on phase-3 clinical trials conducted in the frontline treatment setting for HL. Concerning areas of clinical significance where no comparative trial data is available, data from phase-2 trials or real-world analyses will be briefly discussed.Expert opinionConsolidative radiotherapy is no longer a strict necessity in eHL cases with complete response to frontline chemotherapy and the decision to irradiate in such cases should be individualized. The state-of-the-art in managing aHL requires the use of either BV or nivolumab as introduced by the GHSG HD21 and SWOG S1826 trials, respectively.

Source

Publisher

Taylor and Francis Ltd

Citation

item.page.haspartof

Source

Expert Opinion on Biological Therapy

item.page.ispartofseries

item.page.edition

DOI

10.1080/14712598.2025.2519524

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators